Jennison Associates LLC Has $6.15 Billion Holdings in Eli Lilly and Company (NYSE:LLY)

Jennison Associates LLC decreased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 3.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,947,395 shares of the company's stock after selling 285,593 shares during the period. Eli Lilly and Company comprises approximately 3.8% of Jennison Associates LLC's holdings, making the stock its 7th largest holding. Jennison Associates LLC owned 0.73% of Eli Lilly and Company worth $6,154,975,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in LLY. International Assets Investment Management LLC raised its stake in shares of Eli Lilly and Company by 87,091.7% in the 3rd quarter. International Assets Investment Management LLC now owns 12,463,182 shares of the company's stock valued at $11,041,631,000 after purchasing an additional 12,448,888 shares during the period. Capital Research Global Investors grew its position in Eli Lilly and Company by 6.0% during the 1st quarter. Capital Research Global Investors now owns 8,031,531 shares of the company's stock worth $6,248,210,000 after acquiring an additional 453,939 shares during the last quarter. Capital International Investors grew its stake in shares of Eli Lilly and Company by 5.1% in the first quarter. Capital International Investors now owns 6,972,393 shares of the company's stock worth $5,424,243,000 after purchasing an additional 335,560 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Eli Lilly and Company by 5.0% in the second quarter. Dimensional Fund Advisors LP now owns 3,581,075 shares of the company's stock valued at $3,242,296,000 after buying an additional 171,595 shares during the period. Finally, Janus Henderson Group PLC increased its stake in shares of Eli Lilly and Company by 7.3% in the 1st quarter. Janus Henderson Group PLC now owns 3,575,684 shares of the company's stock valued at $2,781,613,000 after acquiring an additional 243,729 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on LLY shares. Guggenheim upped their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a "buy" rating in a report on Friday, August 16th. Barclays dropped their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an "overweight" rating for the company in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft decreased their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a "buy" rating for the company in a report on Monday, November 4th. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an "overweight" rating in a report on Friday, September 13th. Finally, Evercore ISI raised Eli Lilly and Company to a "hold" rating in a research report on Thursday, September 5th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $1,007.94.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares of the company's stock, valued at $4,402,522.40. This represents a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Up 2.8 %

Shares of NYSE LLY traded up $20.27 during midday trading on Wednesday, reaching $750.00. 3,543,426 shares of the company's stock were exchanged, compared to its average volume of 3,178,654. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The business's fifty day moving average price is $875.60 and its two-hundred day moving average price is $870.81. Eli Lilly and Company has a 52-week low of $561.65 and a 52-week high of $972.53. The stock has a market capitalization of $711.99 billion, a PE ratio of 80.40, a price-to-earnings-growth ratio of 2.82 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same period in the prior year, the company posted $0.10 EPS. Eli Lilly and Company's quarterly revenue was up 20.4% on a year-over-year basis. Analysts forecast that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.69%. Eli Lilly and Company's dividend payout ratio is presently 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.